Celyad « Terug naar discussie overzicht

quote:

Garre schreef op 24 maart 2022 16:52:

Hahahah winst ... nou ben benieuwd, misschien dat ze weer een gift hebben gehad.

quote:

SAMOS schreef op 24 maart 2022 17:09:

nabeurs

quote:

groene appel schreef op 24 maart 2022 22:06:

Press Release
March 24, 2022
Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical activity in relapsed/refractory multiple myeloma (r/r MM) patients
Investigation ongoing of findings in CYAD-101-002 Phase 1b trial following announcement of clinical hold by FDA
Cash position of €30.0 million ($34.0 million) as of December 31, 2021
Conference call and webcast scheduled for March 25 at 1:00 p.m. CET / 8:00 a.m. EDT
MONT-SAINT-GUIBERT, Belgium, March 24, 2022 – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced its financial results for the fiscal year 2021 ended December 31, 2021 and provided a business update.

"This is a transformative time for Celyad Oncology as we work towards becoming a leading innovator in the allogeneic CAR T space. Over the past year, our team executed in evaluating our dynamic shRNA proprietary technology platform and introduced our armored CAR T franchise while delivering important updates across our CAR T pipeline. In addition, we expect our recently announced private placement with Fortress Investment Group to act as a catalyst for our corporate initiatives to advance our intellectual property and allogeneic CAR T product candidates,” commented Filippo Petti, Chief Executive Officer of the Company. “Although we are facing a current challenge with the CYAD-101 Phase 1b trial, the safety of our patients is our first priority, and we are focusing our efforts on the current investigation. The situation does not take away from the important work our team is doing and we believe we can look forward to announcing exciting upcoming milestones in 2022.”

A conference call will be held on Friday, March 25th at 1:00 p.m. CET / 8:00 a.m. EDT to review the financial and operating results for full year 2021. Please dial into the call five to ten minutes prior to start time using the appropriate number below and ask to join the “Celyad Oncology SA call”:
United States: + 1 866 652 5200
Belgium: +32 (0) 800 389 13
International: +1 412 317 6060
The conference call will be webcast live and archived within the “Events” section of the Celyad Oncology website.

quote:

groene appel schreef op 25 maart 2022 08:08:

“Hoewel we momenteel geconfronteerd worden met uitdagingen rond de CYAD-101 Fase 1b studie, is de veiligheid van onze patiënten onze eerste prioriteit, en we richten onze inspanningen op het huidige onderzoek”, aldus CEO Filippo Petti in een toelichting op de cijfers, verwijzend naar de stop die op de studie werd gezet na de dood van twee patiënten.

“De situatie doet niets af aan het belangrijke werk dat ons team doet en we geloven dat we kunnen uitkijken naar de aankondiging van spannende komende mijlpalen in 2022”, zei de CEO.